The last 6 years spread out from 2009 -> today 2009-2011 Annual...

The last 6 years spread out from 2009 -> today
2009-2011 Annual Report Data is for comparison and reference
and to put the figures from 2012 onwards in perspective

What did we get for our $s

6.5 million Research & Development
6.3 million in (non-clinical) Trial Expenses
4.5 million in Regulatory Approvals and Intellectual Property protection
3.5 million in Consultants Expenses
3.4 million impairment/writeoff of Inventory
1.0 million in Foreign Exchange losses
and not to forget:
the 6-fold increase in yearly Occupancy Expenses as happened in 2012
the tripling of employment expenses in 2012

Please note that the figures have been compiled from the relevant annual and half-yearly reports.
The directors (with one exception) and senior management have been the same during these years (2012 - March 2015).

It is most worthwhile to note that both Independent Scientific Advisors, Prof. R. Baxter and Prof. K. Harding, did not appear on any report after the AR 2011 issued 10/08/2011  (see http://www.asx.com.au/asxpdf/20111026/pdf/422116t800g8s5.pdf,
http://sydney.edu.au/medicine/people/academics/profiles/robert.baxter.php
http://medicine.cf.ac.uk/person/prof-keith-gordon-harding/publications/).
Given that Prof. Harding was instrumental in the one-and-only human (as opposed to clinical) trial I have asked about his disappearance or fading-out in one of my earlier posts (14254239).  It was kosenar who replied in post 14261960 (quoting Dr. Ziegelaar) that Dr. Harding is still involved and no more trials are required for the CE process.
The problem is that I could not get a recent confirmation (from Cardiff University or the Welsh Wound Innovation Centre) whether or not Prof. Harding is still involved in the use of VG.  Maybe another poster with better access to European resources can step in and clarify this issue.
My guess is that the dropping out of both Scientific Advisors was due to a significant difference in opinion of how to approach and proceed with the CE mark application.